Sponsor:
Trinity Hypertension & Metabolic Research Institute
Code:
NCT05644769
Conditions
Hypertension
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Accepted
Interventions
Determine the presence of Human sequence Ang-(1-12) on no medication
Human sequence Ang-(1-12) on Lisinopril 40mg every day
Brief summary:
Conditions
Hypertension
Study ID
NCT05644769
Start date
Nov 15, 2022
Status verified date
Dec, 2022
Completion date
Mar 31, 2023
Anticipated
Primary completion date
Mar 31, 2023
Anticipated
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Accepted
Enrollment
10 participants
Anticipated
Allocation
Randomized
Intervention Model
Crossover
Primary purpose
Treatment
Arms
active comparator: Determine the presence of the human sequence of Ang-(1-12) in plasma on no medications
active comparator: Determine the presence of human sequence of Ang-(1-12) on Lisinopril 40 mg every day
Interventions
Determine the presence of Human sequence Ang-(1-12) on no medication
Human sequence Ang-(1-12) on Lisinopril 40mg every day
Primary outcome measure
Central contacts
Locations
Punzi Medical Center
Recruiting
Carrollton, Texas, United States, 75006
Contacts
Sponsor
Trinity Hypertension & Metabolic Research Institute
Last update posted
Dec 9, 2022
Last verified
Dec, 2022
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Trinity Hypertension & Metabolic Research Institute on 2022-12-09.